Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 13 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

23%

3 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
7(70.0%)
Phase 4
3(30.0%)
10Total
N/A(7)
Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT07582250Not ApplicableNot Yet Recruiting

A Prospective, Multicenter, Randomized Controlled Clinical Study on the Safety and Efficacy of Biolimus Drug-Coated Balloon (DCB) Versus Drug-Eluting Stent (DES) in the Treatment of De Novo Coronary Artery Lesions

Role: lead

NCT06926400Not ApplicableNot Yet Recruiting

The Effectiveness and Safety of the Coronary Artery Serrated Cutting Balloon Dilation Catheter in the Pre-dilation of Coronary Artery Stenosis Lesions

Role: lead

NCT06385067Not Yet Recruiting

Treatment of Primary Coronary Artery Vascular Lesions With Biolimus Coated Coronary Balloon Dilation Catheter

Role: lead

NCT06291545Not ApplicableUnknown

Effectiveness and Safety of Coronary Scoring Balloon Dilation Catheter in the Pretreatment of Coronary Stenosis Lesions

Role: lead

NCT04733443Not ApplicableUnknown

The Safety and Efficacy of Biolimus in the Treatment of Patients With in Stent Restenosis

Role: lead

NCT02057978Completed

EXCEL-II Stent Vesus EXCEL Stent to Treat the Patients With de Novo Coronary Artery Lesions.

Role: lead

NCT01909869Not ApplicableCompleted

A Pilot First In Man Study of EXCEL-Ⅱto Treat the Patients With de Novo Coronary Artery Lesions

Role: lead

NCT02027870Completed

EXCEL-II DES to Treat the Patients With de Novo Coronary Artery Lesions. (CREDIT-III)

Role: lead

NCT03769623Not ApplicableCompleted

A Randomized Trial of a Biolimus-Coated Balloon Versus POBA in Small Vessel Coronary Artery Disease

Role: lead

NCT03716011Not ApplicableUnknown

A Postmarket Clinical Trial for EXCROSSAL Stent in CAD Patients With 3-month DAPT or 12-month DAPT

Role: lead

NCT00825773Phase 4Unknown

A Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer in the Treatment of Patients With de Novo Coronary Artery Lesions

Role: lead

NCT00331578Phase 4Completed

Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent

Role: lead

NCT00385905Phase 4Completed

Excel Drug-Eluting Stent Pilot Clinical Registry

Role: lead

All 13 trials loaded